BioCryst Pharmaceuticals Inc. has received a $35 million contract with the Centers for Disease Control and Prevention, according to a Securities and Exchange Commission filing on Thursday.

The contract is for up to 50,000 doses of BioCryst’s approved influenza therapy, RAPIVAB, over a five-year period.

BioCryst is a pharmaceutical company focused on the development and commercialization of treatments for patients with rare and serious diseases.

During the base period of Sept. 1, 2018, through Aug, 31, 2019, the Atlanta-based CDC may purchase up to 10,000 doses of RAPIVAB for a total price of approximately $6.9 million.

The CDC has the option in each of the four subsequent years to purchase up to an additional 10,000 doses at the same per unit price.

The CDC’s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency.

“We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security,” said BioCryst CEO Jon Stonehouse in a statement.

RAPIVAB is approved in the U.S. for the treatment of acute uncomplicated influenza in patients two years and older who have been symptomatic for no more than two days.

BioCryst has several ongoing development programs including an oral treatment for hereditary angioedema, galidesivir and a potential treatment for filoviruses.

Its stock was down 16 cents to $7.83 on Thursday.